Tevogen Bio Highlights Trial Data Showing No Dose-Limiting Toxicities Or Significant Adverse Events With TVGN 489; Study Endpoints On Safety, Viral Load Reduction, And Anti-COVID-19 Responses Met
Portfolio Pulse from Benzinga Newsdesk
Tevogen Bio's trial data for TVGN 489 shows no dose-limiting toxicities or significant adverse events. The study met its endpoints on safety, viral load reduction, and anti-COVID-19 responses. 50% of patients were immunocompromised and infected with SARS-CoV-2 variants. All treated patients returned to baseline health within 14 days and showed no long COVID or reinfection at six-month follow-up. The CEO is advocating for patient support and pledges to use assets to combat long COVID and drive medical innovation.
October 08, 2024 | 6:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tevogen Bio's TVGN 489 trial data shows promising results with no significant adverse events and effective COVID-19 response. The CEO is actively advocating for patient support and pledges to use assets to combat long COVID.
The trial data for TVGN 489 is positive, showing no significant adverse events and meeting safety and efficacy endpoints. This is likely to boost investor confidence and positively impact the stock price. The CEO's advocacy and commitment to using assets for combating long COVID further enhance the company's reputation and potential market impact.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100